| Recruiting | A Phase 1 Study of the Safety and Tolerability of CTX-10726 NCT07419841 | Compass Therapeutics | Phase 1 |
| Not Yet Recruiting | Ischemic Preconditioning Reduces the Severity of Acute Kidney Injury After Partial Nephrectomy NCT07497958 | Sun Yat-sen University | N/A |
| Recruiting | CBCT Guided Markerless SBRT for Renal Cell Cancer NCT07402109 | Erasmus Medical Center | N/A |
| Recruiting | Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC NCT07197580 | Telix Pharmaceuticals (Innovations) Pty Limited | Phase 3 |
| Recruiting | Laparoscopic Versus Open Nephrectomy : Clinical Effectivness and Cost Analysis NCT07461090 | Menoufia University | N/A |
| Recruiting | Investigation of Lymph Node Biology in Kidney Cancer NCT07038733 | Yale University | N/A |
| Recruiting | Cabozantinib Dose Skipping as an Alternative to Dose Reductions NCT07077161 | dr. Tom van der Hulle | Phase 2 |
| Recruiting | Sapu003 in Advanced mTOR-sensitive Solid Tumors NCT07369505 | SAPU NANO (US) LLC | Phase 1 |
| Enrolling By Invitation | Safety and Efficacy of Yiwoxidan Anti (AK112) Monotherapy in Patients With Metastatic Renal Clear Cell Carcino NCT07488572 | Sun Yat-sen University | Phase 2 |
| Not Yet Recruiting | A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Ce NCT07165418 | Peking University Cancer Hospital & Institute | Phase 3 |
| Recruiting | CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors NCT07181720 | Chongqing Precision Biotech Co., Ltd | Phase 1 |
| Recruiting | Validation of RCC Predicting Model With Emulated-target Trial NCT07117227 | Peking University Third Hospital | — |
| Not Yet Recruiting | A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma NCT07087158 | Imbioray (Hangzhou) Biomedicine Co., Ltd. | Phase 2 |
| Recruiting | Preoperative Therapy of Super-selective Tumor Artery Embolization Combined With Toripalimab and Axitinib in Ad NCT07172386 | Tianjin Medical University Second Hospital | Phase 2 |
| Recruiting | Ablative Radioembolization of Renal Cell Carcinoma Trial NCT06642220 | Derek W. Cool | Phase 2 |
| Recruiting | ClAmpless, Sutureless PartIAl Nephrectomy for Renal Masses NCT06722807 | University of Florida | N/A |
| Active Not Recruiting | Vorolanib Monotherapy or in Combination With Toripalimab as Adjuvant Therapy for Patients With Intermediate-hi NCT07047001 | Dong Wen | Phase 2 |
| Recruiting | A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advan NCT07172802 | GI Innovation, Inc. | Phase 1 / Phase 2 |
| Recruiting | Multicenter Study of 18F-Labeled NY104 for PET/CT Imaging in Renal Cell Carcinoma NCT06916624 | The Affiliated Hospital of Qingdao University | — |
| Recruiting | Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remov NCT06661720 | Alliance for Clinical Trials in Oncology | Phase 3 |
| Recruiting | PET/CT-Directed Free of Therapy for Metastatic RCC Patients With IMDC Favorable or Intermediate Risk NCT07175480 | Jinling Hospital, China | Phase 2 |
| Terminated | Efficacy and Safety of Finerenone and Empagliflozin in Delaying Renal Function Progression After Radical Nephr NCT06818305 | Jinling Hospital, China | Phase 2 |
| Active Not Recruiting | A Study Based on CT Radiomics for Distinguishing Benign From Malignant Renal Tumors and Assessing Their Aggres NCT07060248 | Second Xiangya Hospital of Central South University | — |
| Recruiting | Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezo NCT06332755 | LG Chem | Phase 1 |
| Completed | Tertiary Lymphoid Structures Related Genes Predicting Prognosis in Clear Cell Renal Cell Carcinoma: a Retrospe NCT06883565 | Ding-Wei Ye | — |
| Completed | The CT-based Deep Learning Model Predicts Complications in Partial Nephrectomy NCT06876584 | Du Lingzhi | — |
| Completed | "Embolization Before Ablation of Renal Cell Carcinoma (EMBARC)" NCT05410509 | University of Alabama at Birmingham | N/A |
| Active Not Recruiting | Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers NCT05891171 | Arcus Biosciences, Inc. | Phase 1 |
| Terminated | Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors NCT05909995 | Incyte Corporation | Phase 1 |
| Recruiting | A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Co NCT05824975 | GI Innovation, Inc. | Phase 1 / Phase 2 |
| Terminated | Perioperative TORIPALIMAB Plus LENVATINIB in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PLUTO) NCT06114940 | Jinling Hospital, China | Phase 2 |
| Active Not Recruiting | Multimodal Machine Learning Characterization of Solid Tumors NCT04687969 | Ciprian Catana, MD, PhD | — |
| Recruiting | Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors NCT05176483 | Exelixis | Phase 1 |
| Active Not Recruiting | A Pilot Study of Blood-based Biomarkers for Response to Immune Checkpoint Inhibitors NCT06630429 | Ohio State University Comprehensive Cancer Center | — |
| Terminated | LITT and Pembrolizumab in Recurrent Brain Metastasis NCT04187872 | University of Florida | Phase 1 |
| Completed | Master Protocol to Study Treatment Patterns, Medication Adherence, Health and Economic Outcomes and Unmet Need NCT04375150 | Pfizer | — |
| Active Not Recruiting | Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Selec NCT03647163 | Vyriad, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cel NCT03634540 | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 2 |
| Terminated | A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Mal NCT03549000 | Novartis Pharmaceuticals | Phase 1 |
| Completed | A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies NCT03538028 | Incyte Biosciences International Sàrl | Phase 1 |
| Terminated | A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Ad NCT03311334 | Sumitomo Pharma America, Inc. | Phase 1 / Phase 2 |
| Completed | Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302) NCT03260894 | Incyte Corporation | Phase 3 |
| Completed | Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients NCT02903914 | Incyte Corporation | Phase 1 |
| Completed | FAZA PET IMAGING IN DETECTING LYMPH NODE METASTASES IN RENAL CELL CARCINOMA PATIENTS NCT03955393 | IRCCS San Raffaele | — |
| Terminated | A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clea NCT02837991 | Celldex Therapeutics | Phase 1 |
| Completed | Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced NCT02646748 | Incyte Corporation | Phase 1 |
| Completed | CT-based Radiomics for Prediction of MIT Family Translocation Kidney Cancer: a Multicenter, Retrospective Clin NCT07181954 | First Affiliated Hospital of Fujian Medical University | — |
| Completed | Computed Tomography Radiomics-Derived Nomogram for Predicting Early Renal Function Decline After Partial Nephr NCT07117786 | First Affiliated Hospital of Fujian Medical University | — |
| Completed | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participan NCT02178722 | Incyte Corporation | Phase 1 / Phase 2 |
| Completed | PET Quantitative Assessments of Solid Tumor Response to Immune Checkpoint Blockade Therapy NCT01666353 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | EARLY_Phase 1 |
| Completed | A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC) NCT01235962 | Novartis Pharmaceuticals | Phase 3 |
| Terminated | Study of Safety and Functional Imaging of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma NCT00520533 | Ludwig Institute for Cancer Research | Phase 1 |
| Completed | Phase 2 Study in Patients With MiT Tumors NCT00557609 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | Phase 2 |
| Completed | Safety Study With the Antibody, cG250, and Isotope, 124-Iodine, to Diagnose Patients With Renal Masses. NCT00199888 | Ludwig Institute for Cancer Research | Phase 1 |